Treatment Plan for Type 2 Diabetes and Chronic Kidney Disease

Treatment plans for Type 2 Diabetes (T2DM) and Chronic Kidney Disease (CKD) are guided by recommendations from the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO), which advocate for individualized strategies to improve glycemic control and reduce cardiovascular and renal complications. GLP-1 receptor agonists have substantial evidence demonstrating benefits including reductions in major adverse cardiovascular events, improved glycemic control, weight loss, and delayed progression of kidney disease. These findings have led to strong guideline support for their use in T2DM patients with CKD.

Despite the benefits, GLP-1 receptor agonists have limitations, including potential gastrointestinal side effects affecting adherence and high medication costs creating access barriers. While they offer renal protection, SGLT2 inhibitors may provide greater nephroprotective benefits in eligible patients. Therefore, treatment decisions must be individualized, considering patient preferences, tolerability, and financial factors.

This case presented challenges in integrating multiple clinical factors and maintaining a patient-centered approach. Selecting an effective diabetes medication for advanced CKD was difficult due to reduced renal function limiting options and requiring careful review of evidence. Addressing medication adherence was also critical, emphasizing the need for a simplified regimen given potential cognitive impairment and documented nonadherence. Additionally, balancing efficacy and safety was key, with the choice of a GLP-1 receptor agonist over insulin therapy prioritizing effectiveness and avoiding hypoglycemia risk in an older patient with advanced CKD.

The process highlighted the significant importance of individualized treatment planning and evaluating the entire clinical picture rather than focusing solely on laboratory values to ensure optimal patient care.